Entropy Neurodynamics (ASX:ENP) Beta: 0.2833 (As of Jun. 24, 2026)


What is Entropy Neurodynamics Beta?

Entropy Neurodynamics ASX:ENP -3.23% Beta is 0.2833 as of Jun. 24, 2026. The stock has 5 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Entropy Neurodynamics's Beta is 0.2833.

Entropy Neurodynamics  (ASX:ENP) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Entropy Neurodynamics Beta Related Terms

Entropy Neurodynamics Beta Historical Data

* Premium members only.

The historical data trend for Entropy Neurodynamics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entropy Neurodynamics Beta Chart

Entropy Neurodynamics Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun25
Beta
Get a 7-Day Free Trial 0.00 0.00 1.34 1.86 1.06

Entropy Neurodynamics Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 1.60 1.33 1.06 1.08

ASX:ENP vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Entropy Neurodynamics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entropy Neurodynamics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's Beta distribution charts can be found below:

* The bar in red indicates where Entropy Neurodynamics's Beta falls into.


Entropy Neurodynamics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2833 mean?
Entropy Neurodynamics (ASX:ENP) has a Beta of 0.2833 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Entropy Neurodynamics and its competitors.
Is Entropy Neurodynamics' Beta too high?
Entropy Neurodynamics' current Beta is 0.2833.
How does Entropy Neurodynamics' Beta compare to VRTX and REGN?
Entropy Neurodynamics' Beta of 0.2833 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Entropy Neurodynamics and its competitors. Entropy Neurodynamics's current Beta is 0.2833. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Fairly Valued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.03 — trading right at its estimated fair value. The current Beta is 0.2833. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current Beta is 0.2833 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entropy Neurodynamics Business Description

Other Exchanges TYPTF:USA
Address 117 Camberwell Road,, Hawthorn East, Suite 1.01, Camberwell, Melbourne, VIC, AUS, 3123
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.